Why the study?
How do disease states (renal/hepatic impairment) and advanced age affect the pharmacokinetics and pharmacodynamics of ACE inhibitors?
How do disease states (renal/hepatic impairment) and advanced age affect the pharmacokinetics and pharmacodynamics of ACE inhibitors?
ACE inhibitor dosing should be individualized based on renal function, as drug elimination strongly correlates with creatinine clearance, while age alone does not significantly alter PK/PD parameters.
Answers are grounded in this paper and cite their sources.
May support renal function-based ACE inhibitor dosing; leaves open prospective validation across broader populations.
The pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors (ACE) in elderly patients and patients with renal and hepatic impairment were examined, and a role for an AUC/EC50 ratio to guide dosing was evaluated. A Medline and International Pharmaceutical Abstracts search was used to identify human studies and abstracts. Relevant data were evaluated and summarized. Dosing regimens were compared using an AUC/EC50 ratio. Most studies evaluating ACE inhibitors in renal impairment report a strong linear correlation between creatine clearance and drug elimination. AUC and EC50 values for these drugs in elderly subjects appear similar to younger and hypertensive patients. There is increased AUC in some patients with hepatic impairment. Pharmacodynamic data are conflicting. Prolonged ACE inhibition is evident in renal impairment but not necessarily other disease states. ACE inhibitor dosing for hypertension is reasonable based on pharmacokinetics and EC50 values. Further individualization of therapy may improve outcomes, and using the threshold AUC/EC50 ratio may help guide appropriate dosing.
No takes yet. Share an insight, caveat, or question.
LeBlanc et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: